This JUNO deal seems to me to be great news for CAR-Ts .It means CELG decided the barriers to entry are high for CAR-Ts.
ill buy then
Fitbit has unbelievable growth and is already profitable, which is a big deal for a newly public company.The valuation is attractive, too. GoPro (GPRO) and Under Armour (UA) both have slower growth rates, yet have higher valuations that Fitbit.
The Fly On The Wall
Breaking News Feed
6/10/2015 Needham & Company LLC Reiterated Rating Positive
Cramer's Mad Dash: FireEye is cheap at this price cybersecurity ...( FEYE )
J&J buys into Achillion's hep C pipeline for up to $1.1B
May 19, 2015 | By Damian Garde
Johnson & Johnson ($JNJ), fighting to keep up with the blockbuster race to launch quick cures for hepatitis C, has agreed to pay as much as $1.1 billion for the rights to Achillion Pharmaceuticals' ($ACHN) pipeline of antiviral treatments.
Under the deal, J&J is making a $225 million investment in its partner and promising up to $905 million in milestone payments in order to get its hands on a group of in-development hep C treatments. The plan is to develop Achillion's drugs in combination with one another and, ideally, come up with a regimen thatcan cure the infection in as few as four weeks. Leading the pipeline is ACH-3102, Achillion's Phase II NS5A inhibitor, followed by the complementary ACH-3422 and sovaprevir.
Do the DD folks.
Goldman Sachs analysts said in a report on Tuesday that the new study shows efficacy across age groups gives HZ/su a meaningful edge over Zostavax, and GSK's product had the potential to achieve peak sales of around 1 billiopounds ($1.5 billion) a year.